Functional Genomics in Pharmaceutical Drug Discovery.
Targeted therapies in personalized medicine require the knowledge about the molecular changes within the patient that cause the disease. With the beginning of the new century, a plethora of new technologies became available to detect these changes and use this information as starting point for drug development. Next-generation genome sequencing and sophisticated genome-wide functional genomics' methods have led to a significant increase in the identification of novel drug target candidates and understanding of the relevance of these genomic and molecular changes for the diseases. As functional genomic tool for target identification, high-throughput gene silencing through RNA interference screening has become the established method. RNAi is discussed with its advantages and challenges in this chapter. Furthermore the potential of CRISPR/Cas9, a gene-editing method that has recently been adapted for use as functional screening tool, will be briefly reviewed.
Bayer Pharma AG, Muellerstr. 178, 13353, Berlin, Germany.
Robert
R
Adams
Bayer Pharma AG, Muellerstr. 178, 13353, Berlin, Germany.
Michael
M
Steckel
Bayer Pharma AG, Muellerstr. 178, 13353, Berlin, Germany. barbara.nicke@bayer.com.
Barbara
B
Nicke
D055808:Drug Discovery; D023281:Genomics; D059014:High-Throughput Nucleotide Sequencing; D034622:RNA Interference
CRISPR/Cas9; Functional genomics; High-content assay; High-throughput screening; RNA interference (RNAi); Short hairpin RNA (shRNA); Short interfering RNA (siRNA)